No connection

Search Results

ARGX vs HLN

ARGX
argenx SE
BULLISH
Price
$700.45
Market Cap
$43.35B
Sector
Healthcare
AI Confidence
88%
HLN
Haleon plc
NEUTRAL
Price
$9.49
Market Cap
$42.18B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ARGX
35.74
HLN
18.98
Forward P/E
ARGX
21.41
HLN
15.63
P/B Ratio
ARGX
5.9
HLN
1.9
P/S Ratio
ARGX
10.2
HLN
3.82
EV/EBITDA
ARGX
35.5
HLN
33.5

Profitability

Gross Margin
ARGX
57.28%
HLN
64.77%
Operating Margin
ARGX
28.07%
HLN
23.17%
Profit Margin
ARGX
30.41%
HLN
15.11%
ROE
ARGX
20.15%
HLN
10.27%
ROA
ARGX
8.95%
HLN
4.67%

Growth

Revenue Growth
ARGX
74.6%
HLN
0.6%
Earnings Growth
ARGX
-32.0%
HLN
92.0%

Financial Health

Debt/Equity
ARGX
0.01
HLN
0.52
Current Ratio
ARGX
5.23
HLN
0.92
Quick Ratio
ARGX
4.62
HLN
0.68

Dividends

Dividend Yield
ARGX
--
HLN
2.01%
Payout Ratio
ARGX
0.0%
HLN
37.08%

AI Verdict

ARGX BULLISH

ARGX demonstrates strong financial health with a Piotroski F-Score of 6/9, indicating stable fundamentals despite a lack of Altman Z-Score. The company exhibits exceptional revenue growth (74.6% YoY) and a robust profit margin (30.42%), supported by a near-zero debt-to-equity ratio and high liquidity. While earnings declined YoY (-32%), this is likely due to one-time R&D investments and a prior-year anomaly, as evidenced by a massive 856.3% YoY EPS growth and consistent earnings surprises. The stock trades at a premium to its Graham Number ($228.72) and intrinsic value ($137.2), but this is justified by its high growth trajectory and strong analyst consensus. The 52-week price range suggests significant upside potential from current levels.

Strengths
Piotroski F-Score of 6/9 indicates stable financial health with strong operational efficiency
Exceptional revenue growth of 74.6% YoY and 856.3% YoY EPS growth signal strong business momentum
Near-zero debt-to-equity (0.01) and high liquidity (current ratio 5.23) reflect pristine balance sheet
Risks
Significant YoY earnings decline (-32%) despite revenue growth, suggesting potential R&D or cost pressures
Current price of $700.45 is substantially above both Graham Number ($228.72) and intrinsic value ($137.2), indicating high valuation risk
Forward P/E of 21.41 is elevated relative to sector average (164.66), though justified by growth expectations
HLN NEUTRAL

Haleon plc presents a stable fundamental profile with a Piotroski F-Score of 6/9 and a current price of $9.49 that sits comfortably between its Graham Number ($7.49) and Intrinsic Value ($14.75). While the company exhibits strong profitability margins and a healthy debt-to-equity ratio of 0.52, it is hampered by stagnant revenue growth (0.60%) and a completely bearish technical trend (0/100). The massive spike in earnings growth (92%) appears decoupled from top-line performance, suggesting efficiency gains rather than market expansion. Overall, the stock is a value-play with limited immediate momentum.

Strengths
Strong gross margins at 64.77% and operating margins at 23.17%
Conservative leverage with a Debt/Equity ratio of 0.52
Stable financial health indicated by a Piotroski F-Score of 6/9
Risks
Near-zero revenue growth (0.60% YoY) indicating market saturation or lack of pricing power
Severe bearish technical momentum (Technical Trend: 0/100)
Liquidity concerns with a Quick Ratio of 0.68 and Current Ratio of 0.92

Compare Another Pair

ARGX vs HLN: Head-to-Head Comparison

This page compares argenx SE (ARGX) and Haleon plc (HLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile